

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 90087

Title: High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02968018

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Brazil

Author's Country/Territory: India

Manuscript submission date: 2023-11-23

Reviewer chosen by: Huo Liu

Reviewer accepted review: 2023-12-22 11:49

Reviewer performed review: 2023-12-24 14:06

Review time: 2 Days and 2 Hours

| | |
|---|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Novelty of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty |
| Creativity or innovation of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation |

| | |
|---|--|
| Scientific significance of the conclusion in this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
| | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

Overall, this editorial entitled HD-MTX and zanubrutinib combination therapy in PCNSL is well-written and contains useful information. The discussion of the the topic was well done and well-founded. The bibliography is pertinent and current. Minor modifications have been suggested. I would suggest the authors include the following topic and references in the abstract: Primary central nervous system lymphoma (PCNSL) is an unusual form of extranodal non-Hodgkin lymphoma that may affect the brain, leptomeninges, spinal cord or eyes, representing 3% of all intracranial neoplasms Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017:565-577. Makhdoomi R. Primary CNS lymphoma in immunocompetent: a review of literature and our experience from Kashmir. Turk Neurosurg. 2011;21(1):39-47. Beraldo GL. Primary infratentorial diffuse large B-cell lymphoma: a challenging diagnosis in an immunocompetent patient. Rev Assoc Med Bras (1992). 2019 Feb;65(2):136-140.